Eli Lilly and Company (LLY)vsStrata Critical Medical, Inc. (SRTA)
LLY
Eli Lilly and Company
$1,430.13
-0.70%
HEALTHCARE · Cap: $1.26T
SRTA
Strata Critical Medical, Inc.
$5.77
-3.99%
HEALTHCARE · Cap: $392.79M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 33678% more annual revenue ($86.46B vs $255.97M). LLY leads profitability with a 31.9% profit margin vs 15.7%. LLY earns a higher WallStSmart Score of 74/100 (B).
LLY
Strong Buy74
out of 100
Grade: B
SRTA
Buy51
out of 100
Grade: C-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 68 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 53.7%
Revenue surging 38.6% year-over-year
Generating 8.2B in free cash flow
Revenue surging 60.7% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Areas to Watch
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 31.6x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -9.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 53.7%. Revenue growth of 38.6% demonstrates continued momentum.
Bull Case : SRTA
The strongest argument for SRTA centers on Revenue Growth, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 15.7% and operating margin at -6.3%. Revenue growth of 60.7% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.0x leaves little room for execution misses.
Bear Case : SRTA
The primary concerns for SRTA are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
SRTA carries more volatility with a beta of 2.43 — expect wider price swings.
SRTA is growing revenue faster at 60.7% — sustainability is the question.
LLY generates stronger free cash flow (8.2B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (74/100 vs 51/100), backed by strong 31.9% margins and 38.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Strata Critical Medical, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Strata Critical Medical, Inc. provides time critical logistics solutions and specialized medical services to healthcare providers across the United States. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?